Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of…
Height Gain is Maintained in 2nd Year of Treatment
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University…
-
Noosa News22 hours agoMajor crash on Gateway Motorway snarls morning commute
-
Business23 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
Business19 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
General22 hours agoMelbourne AFLW skipper Kate Hore backs league’s future, citing rising skills and talent